These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27152857)

  • 1. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
    Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
    Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
    Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
    J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
    J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of
    van Rossum PSN; Fried DV; Zhang L; Hofstetter WL; Ho L; Meijer GJ; Carter BW; Court LE; Lin SH
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):71-80. PubMed ID: 27511188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer.
    Makino T; Yamasaki M; Tanaka K; Tatsumi M; Takiguchi S; Hatazawa J; Mori M; Doki Y
    Surgery; 2017 Oct; 162(4):836-845. PubMed ID: 28711321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.
    Hegemann NS; Koepple R; Walter F; Boeckle D; Fendler WP; Angele MK; Boeck S; Belka C; Roeder F
    Strahlenther Onkol; 2018 May; 194(5):435-443. PubMed ID: 29349603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
    Ilson DH; Minsky BD; Ku GY; Rusch V; Rizk N; Shah M; Kelsen DP; Capanu M; Tang L; Campbell J; Bains M
    Cancer; 2012 Jun; 118(11):2820-7. PubMed ID: 21990000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.